See also: HIV Viral Load and Viral Suppression
General Information
- Understanding drug resistance (Poz)
- HIV resistance testing (AIDS InfoNet) and Spanish and Russian versions
- Resistance (The Well Project)
- What Is Drug Resistance (AIDSmap)
- HIV genotypic resistance testing (labtestsonline)
- HIV/AIDS drug resistance (TheBody)
Selected Recent Articles
- Patients who fail modern HIV regimens show high prevalence of older mutations. (December 2016, Hepmag)
- High level of drug resistance found among Mexican patients with HIV. (September 2016, Healio)
- Assessing Benefits of Pre-Exposure Prophylaxis Relative to Risks of Drug Resistance. (September 2016, TheBodyPro)
- New HIV Resistance to Antiretrovirals Almost Disappears in Switzerland. (September 2016, HIV Treatment Alerts/TheBodyPro)
- Acquired HIV Antiretroviral Resistance Is a ‘Well-Controlled Relic’ in Switzerland. (August 2016, TheBodyPro)
- Advances in ART reduce drug resistance. (August 2016, Healio)
- Sentosa genotyping assay detects HIV drug resistance mutations. (August 2016, Healio)
- No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial. (July 2016, HIV iBase)
- Viral load pilot study shows roll-out will depend on an educated workforce. (July 2016, AIDSmap)
- Integrase Inhibitors Work Well to Treat NNRTI Drug Resistant HIV. (July 2016, Beta Blog)
- Many U.S. communities vulnerable to HIV outbreak due to unsafe injecting of prescription opioids. (June 2016, AIDSmap)
- Acquisition, impact of HIV drug resistance differs in children, adults. (June 2016, Healio)
- Alarmingly High Levels of HIV Drug Resistance in Those Failing Treatment in Kenya. (June 2016, Poz)
- Acquisition, impact of HIV drug resistance differs in children, adults. (June 2016, Healio)
- Very high levels of drug resistance seen in people experiencing first-line antiretroviral therapy failure in Kenya. (May 2016, AIDSmap)
- HIV rapidly develops resistance to gene-editing cure technology. (May 2016, AIDSmap)
- ARV resistance greater among youth with perinatal HIV. (May 2016, Healio)
- Transmitted drug resistance: The other side to the PrEP failure case we’re not talking about. (May 2016, Beta Blog)
- Resistance to anti-HIV drugs in steep decline in Switzerland. (April 2016, AIDSmap)
- Drug resistance is ‘uncommon,’ but clinicians must remain vigilant. (April 2016, Healio)
- Transmitted HIV Medication Resistance is Increasing, Mostly Among Non-Nukes. (March 2016, Poz)
- Meet the Man Who Got HIV While on Daily PrEP. (March 2016, Poz); related coverage from Healio
- Almost-certain case of PrEP failure due to drug resistance reported at Retrovirus Conference conference. (February 2016, AIDSmap); related coverage from Beta Blog and Poz, Project Inform, and TheBody
- Tenofovir resistance may develop after HIV treatment failure in over half in sub-Saharan Africa. (February 2016, AIDSmap); related coverage from Poz
- Viread resistance common in many low-, middle-income countries. (January 2016, Healio)
- Undetectable & Low-level HIV Viral Replication. (January 2016, Beta Blog)
- HIV subtypes may influence treatment failure. (January 2016, Healio)
- Drug Resistance from Truvada as PrEP Does Not Last. (December 2015, Poz)
- Drug resistance acquired during HIV PrEP rapidly disappears after medication is discontinued. (December 2015, AIDSmap)
- Death during MDR-TB treatment more likely in people with HIV and underweight or most drug-resistant patients. (December 2015, AIDSmap)
- Detectable Viral Load Below 50 Copies Linked to 2-Year Viral Rebound Risk. (December 2015, TheBodyPro)
- Transmission of HIV drug resistance remains stable in Europe. (December 2015, Healio)
- No transmission of integrase inhibitor-resistant HIV seen in California patients. (October 2015, AIDSmap)
- HIV Meds Should Work for Most Drug-Resistant Strains in the U.K. (July 2015, Poz)
- Transmitted HIV drug resistance is persistent but is not harming treatment responses in the UK. (June 2015, AIDSmap)
- Drug resistance possible risk for PrEP. (April 2015, Healio)
- Few mutations implicated in transmission of drug-resistant HIV. (April 2015, Healio)
- PrEP and Drug Resistance: Cause for Concern? (April 2015, Beta Blog)
- While Rare, Drug Resistance After Contracting HIV on PrEP Can Occur. (January 2015, Poz)
- What are the barriers that could stop HIV treatment becoming HIV prevention? (November 2014, AIDSmap)
- Emerging epidemic of transmitted HIV drug resistance in low- and middle-income countries, with highest burden seen in MSM. (October 2014, AIDSmap)
- New HIV Drug Resistance Test Works With Undetectable Viral Load. (October 2014, Poz)
- Longer time to virological failure and less drug resistance seen in people taking Atripla than in people taking separate drugs. (September 2014, AIDSmap)
- Time to first-line failure in the IeDEA cohort. (August 2014, HIV i-Base)
- Tivicay Suppresses HIV Well, Even With Nuke Resistance. (August 2014, Poz)
- Switching From First-Line ART When Suppressed Boosts Failure Chance. (July 2014, NATAP)
- Dolutegravir demonstrates good efficacy despite resistance. (July 2014, AIDSmap)
- DTG-Based Regimens Are Active in INI-Naive Patients With a History of NRTI Resistance. (July 2014, NATAP)
- Effect of viral suppression below 20 copies of HIV-RNA /mL of plasma on virological outcome of treated HIV- infected patients. (July 2014, NATAP)
- Failure Risk Similar With 20 to 50 Copies and Always Under 20 Copies. (July 2014, NATAP)
- Good Response and Resistance Record in Naive and Experienced Starting Dolutegravir. (July 2014, NATAP)
- High rates of drug resistance among HIV-positive infants in South Africa. (July 2014, AIDSmap)
- Changing Meds May Be Unneeded After PI Treatment Failure. (June 2014, Poz)
- People starting therapy on a boosted protease inhihibitor don’t need to switch after one virological failure episode, study indicates. (June 2014, AIDSmap)
- Seroconverting on PrEP Not a Major Risk For Truvada Resistance. (May 2014, Poz)
- No significant risk of resistance if HIV infection occurs during use of Truvada PrEP. (May 2014, AIDSmap)
- Transmitted HIV Resistance Rate Close to 20% in Large Study of U.S. MSM. (March 2014, NATAP)
- Successful HIV drug resistance testing is possible when viral load is low. (January 2014, AIDSmap)
- Most MSM Who Transmit Drug-Resistant HIV Are Not on Treatment. (November 2013, CDC)
- People who aren’t taking HIV treatment are a major source of transmitted resistance in Swiss gay men. (November 2013, AIDSmap)
- A Fond Farewell to the “Virtual Phenotype” Test. (November 2013, Journal Watch)
- Rates of Failure in HIV Drugs Vary Widely in Poorer Nations. (November 2013, Poz)
- Baseline Viral Load, Time to Suppression Dictate Rebound Risk. (November 2013, Poz)
- Long-Acting HIV Drugs Could Extend Lives of Low Adherers. (November 2013, Poz)
- HIV rebound linked to higher baseline level, slower suppression and low-level viraemia. (October 2013, AIDSmap)
- HIV Rebound Risk May Be Predicted by Baseline Viral Load, Time to Viral Suppression. (October 2013, TheBodyPro)
- Number of people infected with drug-resistant HIV in Europe has risen by around 35%. (October 2013, AIDSmap)
- Solving the HIV Treatment Adherence Enigma. (October 2013, TheBodyPro)
- Big differences in virological outcomes among people taking first-line HIV therapy in resource-limited settings. (October 2013, AIDSmap)
- Novel NNRTI AIC292 works well against drug-resistant HIV. (September 2013, AIDSmap)
- Even Very Low Viral Loads Can Lead to Treatment Failure. (September 2013, Poz)
- Persisently detectable viral load at any level increases risk of HIV treatment failure. (August 2013, AIDSmap)
- Nevirapine dose escalation for children may risk treatment failure. (June 2013, AIDSmap)
- Test-And-Treat Would Slow HIV Spread, Improve Health Outcomes, but Raise Drug Resistance. (March 2013, Poz)
- Change in Rates of Transmitted Drug-Resistant HIV. (March 2013, Poz)
- Virologic Failure in 40% of Perinatally Infected US Children – Regimen Switching Slow. (March 2013, NATAP)
- Routine viral load monitoring almost halves risk of virologic failure in 18-month Kenyan study. (March 2013, AIDSmap)
- Resistance to Darunavir Falling Since Approval of the Protease Inhibitor in 2006. (March 2013, NATAP)
- Can people with resistant HIV omit NRTIs when switching from a failing regimen? (March 2013, AIDSmap)
- Wide US Study Finds 16% With Newly Diagnosed HIV Carry Resistant Virus. (March 2013, NATAP)
- HIV Meds Can Still Benefit Those with Triple-Class Failure. (January 2013, Poz)
- Nigeria: Drug resistance data show merits of using tenofovir in first-line ART regimens. (January 2013, AIDSmap)
- Australian researchers project that many HIV-positive people will run out of treatment options. (January 2013, AIDSmap)
- Prevalence of drug-resistant HIV has fallen dramatically among antiretroviral-experienced patients in Western Europe. (January 2013, AIDSmap)